Table 4 Summary of adverse events in the intention-to-treat population
Pyronaridine–artesunate (n = 101) | Artemether–lumefantrine (n = 96) | |
|---|---|---|
Adverse event leading to discontinuation of study drug | ||
Vomiting | 1 (0.99) | 1 (1.04) |
Adverse event of any cause | ||
Patients with at least 1 event | 42 (41.6) | 33 (34.4) |
Headache | 10 (9.90) | 10 (10.4) |
Vomiting | 10 (9.90) | 5 (5.21) |
Cough | 18 (17.8) | 15 (15.6) |
Abdominal pain | 3 (2.97) | 6 (6.25) |
Anorexia | 4 (3.96) | 6 (6.25) |
Diarrhoea | 2 (1.98) | 4 (4.17) |
Chills | 2 (1.98) | 0 |
Fatigue | 4 (3.96) | 1 (1.04) |
Myalgia | 1 (0.99) | 1 (1.04) |
Nasopharyngitis | 3 (2.97) | 4 (4.17) |
Dizziness | 1 (0.99) | 0 |
Skin rash | 2 (1.98) | 1 (1.04) |
Dark urine | 1 (0.99) | 1 (1.04) |
Ear pain | 0 | 1 (1.04) |
Chest pain | 0 | 2 (2.08) |
Throat pain | 1 (0.99) | 0 |
Neck pain | 0 | 1 (1.04) |